Breaks Categories: News

ThursdayNov 04, 2021 10:57 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Schedule I Manufacturing License from DEA

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM), has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (“DEA”). Granted for Cybin’s research lab located in the Boston area, the license is required for investigators who plan to study, produce, analyze or otherwise work with Schedule I controlled substances. According to the announcement, the company is working to become a hub for innovation and drug discovery. Cybin has relied on in-house capabilities as well as globally licensed research organizations in the United States, Canada and the United Kingdom for most…

Continue Reading

ThursdayNov 04, 2021 10:46 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will participate in Wonderland: Miami, presented by Microdose. The event is set to take place Nov. 8-9, 2021, in Miami, Florida. Tryp’s chairman and CEO Greg McKee will participate in a panel discussion entitled, “Developing Psychedelic Medicine Beyond What We Already Know,” beginning at 2:40 p.m. ET on Nov. 8. In the discussion, McKee will highlight Tryp's leading-edge work with synthetic psilocybin for chronic pain and other indications. To view the full press release, visit https://ibn.fm/Dwyv8…

Continue Reading

TuesdayNov 02, 2021 11:02 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a phase 2a clinical trial. Conducted with Kevin Boehnke, Ph.D. from the University of Michigan, the trial seeks to investigate safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration with the University of Michigan and will evaluate the company's oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.…

Continue Reading

TuesdayNov 02, 2021 10:32 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough preclinical, research findings that indicate advancements in the company’s focus on creating a promising approach for patients in need of effective and safe prescription therapies in the mental health space. Cybin CEO Doug Drysdale and other key members of the company’s senior scientific research team will be hosting the event, which will be held during the Wonderland Conference in Miami;…

Continue Reading

MondayNov 01, 2021 12:21 pm

PsychedelicNewsBreaks – IBN and PsychedelicNewsWire to Broaden Reach for Upcoming Wonderland Miami Conference

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that it, together with its PsychedelicNewsWire (“PNW”) brand, will further collaborate with Microdose Psychedelic Insights for the upcoming Wonderland Miami Conference. The event is slated to take place at Miami’s Adrienne Arsht Center for the Performing Arts on Nov. 8-9, 2021. The premier destination for the psychedelic industry, Wonderland: Miami provides an ideal opportunity to connect with influential leaders in science, policy and business. Roger McIntyre, M.D., FRCPC CEO and director, Braxia Scientific (ICX: BRAX), Lamar Odom, former professional American basketball player, and Zappy Zapolin, psychedelic concierge, are among…

Continue Reading

ThursdayOct 28, 2021 12:36 pm

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has signed a nonbinding letter of intent with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF). Awakn is a biotechnology company with clinical operations focused on researching, developing and delivering psychedelic medicine to better treat addiction. According to the agreement, MINDCURE will distribute Awakn’s ketamine-assisted psychotherapy for alcohol use disorder protocol via its digital therapeutics platform, iSTRYM. Distribution began in August when MINDCURE released the minimum viable product version of iSTRYM into partner clinics across North America with full commercial deployment to all partner clinics slated for…

Continue Reading

ThursdayOct 28, 2021 11:04 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unveils Psychedelic Facilitator Training Program Based on Groundbreaking Psychotherapy Approach

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is launching its own psychedelic facilitator training program. Called EMBARK, the project is led by expert faculty and provides psychedelic clinical trial facilitators with fundamental training to provide skillful, ethical care to individuals receiving psychedelic treatment. EMBARK emphasizes experiential learning and includes an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state as well the training and practice sessions on the EMBARK model, a groundbreaking psychotherapy approach that incorporates psychedelic medicine with leading clinical approaches designed to promote supportive healing.…

Continue Reading

WednesdayOct 27, 2021 11:11 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speakers for World’s Premiere Psychedelic, Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that COMPASS Pathways execs George Goldsmith and Ekaterina Malievskaia MD will be featured speakers at next month’s Meet Delic event. Meet Delic is a revolutionary, two-day immersive edutainment experience designed to gather together the world's leading psychedelic and wellness thought and business leaders. The two-day event is scheduled for Nov. 6–7, 2021, in Las Vegas. Goldsmith, CEO and cofounder of COMPASS Pathways, and Malievskaia, also cofounder and chief innovation officer, will participate in a keynote interview focused on exploring the company’s…

Continue Reading

WednesdayOct 27, 2021 10:24 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Successfully Synthesizes Novel Psilocin Analogue

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized a novel psilocin analogue, a tryptamine. This achievement means improved pharmaceutical properties to further strengthen MYCO’s library of patent-pending tryptamines. According to the announcement, the synthesis of the tryptamine results in the company adding a new compound to its growing library of compounds, supporting Mydecine’s commitment to improve the safety and efficacy of its drug-development candidates for use in therapy and medical practice. Since 2021 Mydecine has been working with Applied Pharmaceutical Innovation…

Continue Reading

WednesdayOct 27, 2021 10:22 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Sponsor, Participate In Upcoming Events

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, announced its participation in two upcoming November events. The company will be a silver sponsor of Wonderland Miami, the largest in-person conference focused on the psychedelic medicine industry. At Wonderland, MINDCURE president and CEO Kelsey Ramsden will participate in several panel discussions scheduled during the in-person, two-day event. Slated for Nov. 8–9, 2021, Wonderland Miami is presented by Microdose Psychedelic Insights, a portfolio company of Origin Therapeutics. In addition, MINDCURE is also scheduled to participate in next month’s International Summit on Psychedelic Therapies for…

Continue Reading